Additionally in vitro experiments attributed expression of wildtype TP53 or mutational TP53 and/or loss of TP53 to differential drug response in several CLL cell lines, including JVM-3 and MEC-1 (73–75). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.